A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis

Condition: Multiple sclerosis

Category: Rheumatology

Author: Maira Gironi

Date: Oct 2008

Type: Article

A sixth month trial with a low dose of the opiate antagonist Naltrexone (LDN) carried out in 40 patients with primary progressive multiple sclerosis (PPMS). The biological impact on the opioid system of LDN administration was also evaluated together with the allelic variants of the human MOR gene OPRM1.

Not Finding What You're Looking For?

Fill out the form below to let us know.

>